XAIR vs. APYX, DXR, AMIX, HSAQ, SRTS, CTSO, NSPR, CTCX, LUCD, and ICU
Should you be buying Beyond Air stock or one of its competitors? The main competitors of Beyond Air include Apyx Medical (APYX), Daxor (DXR), Autonomix Medical (AMIX), Health Sciences Acquisitions Co. 2 (HSAQ), Sensus Healthcare (SRTS), Cytosorbents (CTSO), InspireMD (NSPR), Carmell (CTCX), Lucid Diagnostics (LUCD), and SeaStar Medical (ICU). These companies are all part of the "surgical & medical instruments" industry.
Apyx Medical (NASDAQ:APYX) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 13.1% of Apyx Medical shares are owned by company insiders. Comparatively, 19.0% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Apyx Medical currently has a consensus target price of $6.17, suggesting a potential upside of 376.19%. Beyond Air has a consensus target price of $11.25, suggesting a potential upside of 822.13%. Given Apyx Medical's higher possible upside, analysts plainly believe Beyond Air is more favorable than Apyx Medical.
Beyond Air has a net margin of 0.00% compared to Beyond Air's net margin of -35.75%. Beyond Air's return on equity of -54.90% beat Apyx Medical's return on equity.
In the previous week, Apyx Medical and Apyx Medical both had 1 articles in the media. Apyx Medical's average media sentiment score of 1.29 beat Beyond Air's score of 0.00 indicating that Beyond Air is being referred to more favorably in the news media.
Apyx Medical has higher revenue and earnings than Beyond Air. Apyx Medical is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Apyx Medical received 34 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.25% of users gave Beyond Air an outperform vote while only 61.60% of users gave Apyx Medical an outperform vote.
Apyx Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500.
Summary
Apyx Medical beats Beyond Air on 8 of the 15 factors compared between the two stocks.
Get Beyond Air News Delivered to You Automatically
Sign up to receive the latest news and ratings for XAIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XAIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Beyond Air Competitors List
Related Companies and Tools